Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors Abstract #143

Introduction: In the absence of preoperative somatostatin receptor (sst) scans, knowledge of immunohistochemical sst2 tumor expression may help in predicting the success of somatostatin analogue-based follow-up studies and treatment of neuroendocrine tumors (NETs).
Aim(s): We studied the association between sst immunostaining and tracer uptake in [111In]-DTPA octreotide (DTPAOC) scintigraphy and [68Ga]-DOTA-D-Phe(1)-Tyr(3)-Octreotide (DOTATOC) positron emission tomography (PET)/computed tomography (CT).
Materials and methods: Retrospective analysis of 36 NET patients. In 40 tumors, immunohistochemical sst2, sst3, and sst5 expression was analysed using a pathological scoring, applying monoclonal (sst2) or polyclonal antibodies (sst3, sst5). In 14 lesions, [111In]-DTPAOC uptake was assessed by a semiquantitative score. In 26 tumors, [68Ga]-DOTATOC PET/CT was quantified using an uptake score and maximal standard uptake value (SUVmax).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Karsten Müssig

To read results and conclusion, please login ...

Further abstracts you may be interested in

#120 Somatostatin receptors 1-5 expression in a large series of well-differentiated neuroendocrine tumors
Introduction: For their antisecretive and antiproliferative effect somatostatin analogs (SA) have been used in the treatment of neuroendocrine tumors (NETs), based on the expression of somatostatin receptors (sstRs). The potential availability of new SA for the treatment of patients with NETs suggests a better characterization of sstRs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Paola Loli
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#512 Epidemiology of Neuroendocrine Tumors in France: The PRONET Study
Introduction: Because of recent progress in neuroendocrine tumor treatment (NET), more data are required about this pathology in France.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Xavier Parot
#1998 Vitamin D, Bone Mineral Density and Fracture Risk Assessment in Patients with Neuroendocrine Tumors
Introduction: Some papers have recently described an association between neuroendrocrine tumors (NET) and both vitamin D deficiency (VDD) and low bone mineral density (BMD). The ten-year risk of osteoporotic fractures can be calculated with the FRAX algorithm.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Franco Grimaldi
#2207 Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study
Introduction: Specific biomarkers for predicting response and risk of recurrence after surgery for enteropancreatic neuroendocrine tumours (EP-NETs) are still lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Francesca Muffatti